2nd International Conference on Metabolic and Bariatric Surgery June 12-12, 2017 Rome, Italy

Jan Paul J. Mulier is chairman of the department of Anesthesiology, Intensive care and Emergency Care at the AZ Sint Jan Brugge-Oostende in Belgium. He holds a specialization in Anesthesiology, Intensive and Emergency Care from the KUL; he was a visiting resident at the Anesthesiology department UCSF in San Francisco, California. In 1989 he served as a researcher for paired pacing at Medtronic, Inc, at Minneapolis, and got an MBA at Vlerick in the management of research and innovation

Anesthesiology, Intensive care and Emergency Care

Mohammed Khalid Mirza Gari, FRCS (Ireland), Consultant General, Laparoscopic and Bariatric Surgeon, Division Head, Department of Surgery, Imam Abdulrehman Bin Faisal Hospital, National Guard Health Affairs, Dammam, Saudi Arabia

He is Interested in Laparoscopic and Bariatric Surgeries

Dr. Claudio Blasi graduated in medicine from Rome “La Sapienza” University at the age of 27 and did a postgraduate specialization in endocrinology at “La Sapienza” School of Medicine. He has been the director of the ASLRMB-1D hospital diabetes center in Rome. He has published more than 30 papers in reputed journals

He is interested in the Endocrinology, Diabetics and Bariatric Surgery

He is working as an Aesthetic Plastic Surgeon in his own private setup called Reshape. As an Aesthetic Plastic Surgeon he had performed more than 6,000 procedures with main interests in Abdominoplasty, liposuction, breast surgery, rhinoplasty, face and neck lift, eye lid surgeries, arm lift, thigh lift and body lifts.

Abdominoplasty, liposuction, breast surgery, rhinoplasty, face and neck lift, eye lid surgeries, arm lift, thigh lift and body lifts.

Associate Professor Signe Torekov has a strong background in metabolic translational research. In collaboration with University of California her research has shown that infusion of the natural appetite hormone GLP-1 inhibits appetite and lowers blood glucose (2 first authorships in Diabetes, Obesity and Metabolism (Impact factor (IF) 6.2), 2011 and 2013). During the last three years, her research team has discovered that: 1) obese people have low endogenous GLP-1 response (first author in Diabetes (IF8.4), 2015); 2) weight loss induces a marked increase in GLP-1 response and that this is part of a successful maintenance of weight loss (last author in European Journal of endocrinology (IF4.1), 2016) (major media exposure: front page interview of The Times and live on BBC Today, April 2016 (7 mill listeners), and 3) treatment with GLP-1 analogues facilitate long term weight loss maintenance accompanied by substantial improvement in metabolic health, compared to diet-induced weight loss maintenance (Last author in Journal of Clinical Endocrinology and Metabolism (IF6.4) and International Journal of Obesity (IF5.4), 2015). Furthermore, by synergistically integrating metabolic physiology with novel state of the art mass spectrometry based proteomics and metabolomics, in collaboration with Professor Matthias Mann, Max Planck Institute, they have designed a novel experimental approach for clinical translational metabolism in order to identify new health markers in obesity (2. last author in Molecular Systems Biology, (IF 12.3) and last author in Metabolomics (IF3.7), 2016). In addition, Signe Torekov was awarded Major Discovery 2010-2015 for the her first author paper in Diabetes (IF8.4) 2014 where she, together with the research team, showed that Long QT Syndrome patients with mutations in KCNQ1 besides having prolonged cardiac arrhythmia, also have hyperinsulinemic hypoglycemia. More recently, Signe Torekov has shown that Long QT Syndrome patients with loss of function mutations in hERG display exaggerated incretin and endocrine pancreatic function and thus increased risk of symptomatic reactive hypoglycemia. Pharmacological blockade in rats and inhibition of hERG in β and L- cells had similar effects. Hypoglycemia leads to increased propensity for arrhythmias; hypoglycemia may therefore even further increase the risk of malignant arrhythmia in LQTS patients (published in Circulation (IF17) with Dr. Torekov as last and corresponding author). In total, Signe Torekov has authored 30 original peer-reviewed papers, much of this work has been published in high-ranking journals in the field (Diabetes, JCEM, Diabetologia DOM, Molecular Systems Biology (16 first and 10 last authorships), h-index of 14 (i10-index 17) and a total of 1053 citations (Google scholar, March 2017). Moreover, she has received major international media interest for the papers in EJE 2016, JCEM and Diabetes 2015. She has received Several Young Investigator Awards. In 2016, she received the prestigious Novo Nordisk Foundation Excellence Fellowship of 5 million DKK given to excellent young researchers within endocrinology in the Nordic Countries. In 2015, she formed an international alliance in immuno-metabolism with top researchers at Oxford and Karolinska University. Together they received 40 million DKK from the Novo Nordisk Foundation to identify new markers and treatment in immuno-metabolism. Associate Professor Signe Torekov is PI on 3.9 million DKK of this grant.

Diabetes, Obesity and Metabolism

Associate Professor Signe Torekov has a strong background in metabolic translational research. In collaboration with University of California her research has shown that infusion of the natural appetite hormone GLP-1 inhibits appetite and lowers blood glucose (2 first authorships in Diabetes, Obesity and Metabolism (Impact factor (IF) 6.2), 2011 and 2013). During the last three years, her research team has discovered that: 1) obese people have low endogenous GLP-1 response (first author in Diabetes (IF8.4), 2015); 2) weight loss induces a marked increase in GLP-1 response and that this is part of a successful maintenance of weight loss (last author in European Journal of endocrinology (IF4.1), 2016) (major media exposure: front page interview of The Times and live on BBC Today, April 2016 (7 mill listeners), and 3) treatment with GLP-1 analogues facilitate long term weight loss maintenance accompanied by substantial improvement in metabolic health, compared to diet-induced weight loss maintenance (Last author in Journal of Clinical Endocrinology and Metabolism (IF6.4) and International Journal of Obesity (IF5.4), 2015). Furthermore, by synergistically integrating metabolic physiology with novel state of the art mass spectrometry based proteomics and metabolomics, in collaboration with Professor Matthias Mann, Max Planck Institute, they have designed a novel experimental approach for clinical translational metabolism in order to identify new health markers in obesity (2. last author in Molecular Systems Biology, (IF 12.3) and last author in Metabolomics (IF3.7), 2016). In addition, Signe Torekov was awarded Major Discovery 2010-2015 for the her first author paper in Diabetes (IF8.4) 2014 where she, together with the research team, showed that Long QT Syndrome patients with mutations in KCNQ1 besides having prolonged cardiac arrhythmia, also have hyperinsulinemic hypoglycemia. More recently, Signe Torekov has shown that Long QT Syndrome patients with loss of function mutations in hERG display exaggerated incretin and endocrine pancreatic function and thus increased risk of symptomatic reactive hypoglycemia. Pharmacological blockade in rats and inhibition of hERG in β and L- cells had similar effects. Hypoglycemia leads to increased propensity for arrhythmias; hypoglycemia may therefore even further increase the risk of malignant arrhythmia in LQTS patients (published in Circulation (IF17) with Dr. Torekov as last and corresponding author). In total, Signe Torekov has authored 30 original peer-reviewed papers, much of this work has been published in high-ranking journals in the field (Diabetes, JCEM, Diabetologia DOM, Molecular Systems Biology (16 first and 10 last authorships), h-index of 14 (i10-index 17) and a total of 1053 citations (Google scholar, March 2017). Moreover, she has received major international media interest for the papers in EJE 2016, JCEM and Diabetes 2015. She has received Several Young Investigator Awards. In 2016, she received the prestigious Novo Nordisk Foundation Excellence Fellowship of 5 million DKK given to excellent young researchers within endocrinology in the Nordic Countries. In 2015, she formed an international alliance in immuno-metabolism with top researchers at Oxford and Karolinska University. Together they received 40 million DKK from the Novo Nordisk Foundation to identify new markers and treatment in immuno-metabolism. Associate Professor Signe Torekov is PI on 3.9 million DKK of this grant.

Diabetes, Obesity and Metabolism